IL22 and psoriasis: As TH17 cells have been described as main contributors for the development of psoriasis pathology (Kryczek et al., 2008; Lowes et al., 2008), a psoriasis model was induced by treating HSEs with a TH17-derived cytokine mix (IL-17A and IL-22, 30 ng/ml each).